Pfizer: new Emblaveo antibiotic approved in the EU
This antibiotic targets complex intra-abdominal infections, nosocomial pneumonia such as ventilator-associated pneumonia, and urinary tract infections such as pyelonephritis.
It has also been approved for the treatment of Gram-negative bacterial infections, an area where treatment options have hitherto been limited due to multi-drug resistance.
Emblaveo - which was jointly developed with AbbVie - is to be marketed internationally by Pfizer, with AbbVie holding distribution rights in the USA and Canada.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction